血小板血症の骨髄線維症(Thrombocythaemia Myelofibrosis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thrombocythaemia Myelofibrosis Overview 6
Therapeutics Development 7
Pipeline Products for Thrombocythaemia Myelofibrosis – Overview 7
Pipeline Products for Thrombocythaemia Myelofibrosis – Comparative Analysis 8
Thrombocythaemia Myelofibrosis – Therapeutics under Development by Companies 9
Thrombocythaemia Myelofibrosis – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Thrombocythaemia Myelofibrosis – Products under Development by Companies 12
Thrombocythaemia Myelofibrosis – Companies Involved in Therapeutics Development 13
Gilead Sciences, Inc. 13
Incyte Corporation 14
MEI Pharma, Inc. 15
Nippon Shinyaku Co., Ltd. 16
Novartis AG 17
Thrombocythaemia Myelofibrosis – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
buparlisib hydrochloride – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
INCB-39110 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
momelotinib – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NS-018 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
panobinostat – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
pracinostat – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
simtuzumab – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Thrombocythaemia Myelofibrosis – Recent Pipeline Updates 47
Thrombocythaemia Myelofibrosis – Discontinued Products 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60